Correlation Between d-ROM Levels and Recurrence-Free Period in Multicentric Occurrence Cases

Feb 26, 2025

10 likes | 90 Views

Explore the relationship between d-ROM levels and recurrence-free periods in 36 multicentric occurrence cases using linear regression analysis. The study examines the impact of oxidative stress on the duration of disease-free intervals.

Share Presentation

Embed Code

Link

drom levels
recurrencefree period
multicentric occurrence
linear regression

noma

Download Presentation

Correlation Between d-ROM Levels and Recurrence-Free Period in Multicentric Occurrence Cases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplemental Figure 1 d-ROM (Carr U) P = 0.0512 recurrence-free period (day) Correlation between d-ROM levels and recurrence-free periodin 36 multicentric occurrence cases using linear regression analysis

Supplemental Figure 1

Supplemental Figure 1. Fig. S1 qRT -PCR analysis of the genes flanking the sbp2’ / sbp2’’ knockouts. All values are given relative to the abundance of transcript observed in P1/7. Data presents the mean from 3 biological replicates. .

106 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1.

85 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. A. Mock. MOI-100. MOI-10. 0.5%. 79.7%. 21.8%. CD3 PerCP. NY-ESO-1 Tetramer PE. B. C. Supplemental Figure 2. A. Thymus. L Humerus. R Humerus. Muscle. L Femur. R Femur. C. B. P < 0.0001. Supplemental Figure 3. A. B.

167 views • 3 slides

Supplemental Figure 1

Supplemental Figure 1. Isolation of glomeruli in control mice.

116 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. A. P-VEGFR2. Tubulin. PlGF-1 250 ng/mL - + + + + Time (min) - 5 10 15 30. B. P-VEGFR2. Tubulin. C.

105 views • 3 slides

Supplemental Figure 1

A. B. C. D. E. F. Supplemental Figure 1. Supplemental Figure S1. Incidence of CD4+ IFN γ (A) , IL-2 (C) and TNFa (E) responders and magnitude of total IFN γ + (B), IL-2+ (D) and TNFa+ (F) CD4+ T-cell responses in different patient groups

160 views • 6 slides

Supplemental Figure 1

Supplemental Figure 1. SPERM A -. Sp_D62[A-]. Sp_D62[A+]. SPERM A +. Sp_D62[Tt]. SPERM TOTAL. Sp_D64[Tt]. Sp_D66[Tt]. Sp_P1[Tt]. Sp_D62[SP]. SPERM SPIA. Sp_D64[SP]. Sp_D66[SP]. Sp_P2[SP]. Te_PCl[SP]. TESTES SPIA. Te_PAm[A+]. TESTES Poly (A + ). Te_PCl[A+]. PRM2.

187 views • 6 slides

Supplemental Figure 1

Supplemental Figure 1. Patient 2. Supplemental Figure 2. Patient:. 1. 2. 3. No cDNA. No cDNA. No cDNA. - Ac. - Ac. - Ac. - Ac. - Ac. - Ac. IgG. IgG. IgG. IgG. IgG. IgG. IgA. IgA. IgA. IgA. IgA. IgA. Patient:. 4. 5. 6. No cDNA. - Ac. - Ac. - Ac. - Ac.

111 views • 4 slides

Supplemental Figure 1

Supplemental Figure 1. c. . MGC-803. 4. 4. 3. 3. miR-185 levels (fold). 40. TUNEL positive cells (%). 2. 2. . 1. 1. 20. 0. 0. . 60. 60. 0. –. CDDP(30 m M). +. +. +. TUNEL positive cells (%). 40. 40. . –. –. –. miR-185 AntagomiR. +. –. –. –.

83 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. a. Relative expression. b. Relative expression. c. Relative expression.

115 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. B. A. g H2AX. TRF1. Merge. 100. Untreated. 80. 60. % of TIFs positive cells. 40. RHPS4. 20. 0. _. RHPS4. siTRF2. siPOT1. CPT. IR. siTRF2. siPOT1. CPT. IR.

124 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. Supplemental Figure 1 . Southern of AtplaIVC-1

89 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. Supplemental Figure 2. Supplemental Figure 3. A. B. C. D. Supplemental Figure 4. A. B. 231. 231. C. D. 231-Ecad. 231-Ecad. E. F. 231-shEcad. 231-shEcad. G. H. DU-145. DU-145. Supplemental Figure 5. Supplemental Figure 6. Supplemental Figure 7. A.

169 views • 10 slides

Supplemental Figure 1

Supplemental Figure 1. True leaf from 2 nd to 7 th nodes. (a). M. 1 st (IN) IN. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. PC. ALSV-RNA2. 7. PsEF1- a. 6. 1. 2. 3. 5. True leaf from 2 nd to 7 th nodes. ALSV inoculation. 4. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. 3. Mock. 2.

102 views • 3 slides

Supplemental Figure 1

Vimentin. FLAG/Luc/#1. FLAG/Keap1/#1. FLAG/Luc/#1 FLAG/Keap1/#1. B. Supplemental Figure 1. A. Supplemental Figure 2. GSH. 25,000,000. 20,000,000. Relative Intensity. 15,000,000. 10,000,000. 5,000,000. 0. Control. Nrf2 shRNA/#2. Levels of ROS. A. B. Control.

227 views • 10 slides

Supplemental figure 1

Supplemental figure 1. A. B. LFN. naked DNA. C. D. 【 Ad genome 】. 【 pDNA 】. Amount of DNA. Amount of DNA. ( ×10 9 copies). ( ×10 10 copies). 1.1. 2.1. 4.3. 0.85. 1.7. 3.4. 6.8. E. F. 【 Ad genome 】. 【 pDNA 】. 25. 60. y = 8.0×10 -10 x + 0.030 R 2 = 0.989.

87 views • 2 slides

Supplemental Figure 1

Supplemental Figure 1. A. Obj 1. Obj 2. Obj 3. Obj 4. Obj 5. B. Bio16. C. mCT. Transconvolution and the Virtual Positron Emission Tomograph (vPET) – A New Method for Cross Calibration in Quantitative PET/CT Imaging

148 views • 1 slides

Supplemental Figure 1

Serum concentration of cTnT. Activity of MMP-2/9. Before CPB. AfterCPB. Supplemental Figure 1.

85 views • 1 slides

Supplemental Figure 1

2500. 2000. 1500. 1000. 500. Supplemental Figure 1. CS-0777 product [ ng/mL ･ mg protein ]. 0. #1. #2. #3. #4. #5. Human specimen number. Supplemental figure 1. Examination of individual specificity of CS-0777-P phosphatase activity

239 views • 7 slides

Supplemental Figure 1.

Supplemental Figure 1. Immunohistochemistry for Hic-5 in human small intestine. In the epithelial cells, Hic-5 appears to be localized primarily in the apical portion of the epithelium.

88 views • 1 slides

Supplemental Figure 1

B. Axonal Blebbing. t = 0 min. t = 0 min. t = 5 min. t = 5 min. t = 10 min. t = 10 min. t = 15 min. t = 15 min. t = 20 min. t = 20 min. A. Growth Cone Ruffling. D. Average Positive Particle Velocity Histogram. C. WGA Kymograph (4 hr incubation). 0 min. Time. *. 20 min.

202 views • 2 slides

Supplemental Figure 1

Supplemental Figure 1. A. B. panobinostat. Supplemental Figure 2. Control. 20. 50 nM BC2059, 24 hr. A. OCI-AML3. B. Supplemental Figure 2. Control. 20. 50. 100 nM BC2059, 48 hr. C. OCI-AML3. TO-PRO-3 iodide. Annexin V-FITC. D. Control. 50.

140 views • 12 slides

More Related